会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 74. 发明申请
    • BENZODIAZONINE DERIVATIVES BINDING TO CHOLECYSTOKININ OR GASTRIN RECEPTORS
    • 苯并吖嗪衍生物与胆碱酯酶或胃蛋白酶受体结合
    • WO1997032860A1
    • 1997-09-12
    • PCT/GB1997000632
    • 1997-03-07
    • JAMES BLACK FOUNDATION LIMITEDKALINDJIAN, Sarkis, BarretMcDONALD, Iain, MairPETHER, Michael, JohnLOW, Caroline, Minli, RachelSTEEL, Katherine, Isobel, MaryLINNEY, Ian, Duncan
    • JAMES BLACK FOUNDATION LIMITED
    • C07D245/06
    • C07D403/12A61K38/00C07D225/06C07D245/06C07K5/06139C07K5/06191
    • Compounds of formula (I), wherein one of U and V is -CHR -, and the other of U and V is selected from -N(COR )-, -CH(COR )-,-N(SO2R )- and -CH(SO2R )-, in which R is H, -COOR , -CONR R or -COR and R is H, C1 to C6 hydrocarbyl (in which up to three of the carbon atoms may be replaced by a nitrogen, oxygen or sulphur atom), or a group of the formula -Q-R wherein Q is a bond, -NR - (in which R is H or C1 to C3 alkyl) or -O-, and R is aryl, substituted aryl, arylalkyl or (substituted aryl)alkyl; R is independently C1 to C3 alkyl; R is H or C1 to C15 hydrocarbyl wherein one or more hydrogen atoms may be replaced by halogen atoms, and one carbon atom may be replaced by a nitrogen, oxygen or sulphur atom; R is independently halo, alkyl, alkoxy, -NO2, -NH2 or -NHCOR ; X is H and Y is H or C1 to C10 hydrocarbyl wherein one or more hydrogen atoms may be replaced by halogen atoms, and one carbon atom may be replaced by a nitrogen, oxygen or sulphur atom; or X and Y together are =O or =CH2; Z is H, C1 to C15 hydrocarbyl (in which one or more hydrogen atoms may be replaced by a halogen atom, and up to three of the carbon atoms may be replaced by a nitrogen, oxygen or sulphur atom), or -(CHR )m-R (wherein R is H or C1 to C3 alkyl and R is phenyl, substituted phenyl or a group of the formula -COOR or -CONR R , in which R and R are independently H or C1 to C6 alkyl, or R and R together form a propylene, butylene, pentylene or hexylene group); m is from 1 to 3; and n and p are independently from 0 to 3, and pharmaceutically acceptable salts thereof are ligands at gastrin and/or cholecystokinin receptors.
    • 式(I)化合物,其中U和V中的一个为-CHR 2 - ,U和V中的另一个选自-N(COR 4) - , - CH(COR 4) - ,-N(SO 2 R 4) - 和-CH(SO 2 R 4) - ,其中R 2是H,-COOR 5,-CONR 6 R 7或-COR 7 并且R 4是H,C 1至C 6烃基(其中最多三个碳原子可以被氮,氧或硫原子替代)或式-QR 16的基团,其中Q是 R 17 - (其中R 17是H或C 1至C 3烷基)或-O-,R 16是芳基,取代的芳基,芳基烷基或(取代的芳基)烷基; R独立地为C 1至C 3烷基; R 1是H或C 1至C 15烃基,其中一个或多个氢原子可以被卤素原子取代,并且一个碳原子可被氮,氧或硫原子代替; R 3独立地为卤素,烷基,烷氧基,-NO 2,-NH 2或-NHCOR 5; X是H,Y是H或C 1至C 10烃基,其中一个或多个氢原子可以被卤素原子代替,一个碳原子可以被氮,氧或硫原子代替; 或X和Y一起为= O或= CH 2; Z是H,C 1至C 15烃基(其中一个或多个氢原子可以被卤素原子替代,并且多达三个碳原子可以被氮,氧或硫原子替代),或 - (CHR )其中R 18是H或C 1至C 3烷基,R 8是苯基,取代的苯基或式-COOR 9或-CONR 9 R 10的基团 >其中R 9和R 10独立地为H或C 1至C 6烷基,或R 9和R 10一起形成丙烯,亚丁基,亚戊基或亚己基)。 m为1〜3; 且n和p独立地为0至3,其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。